Shanghai Junshi Biosciences Co Ltd (688180.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE1000041Z1
Shanghai Junshi Biosciences Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.95 bn CNY | 2.50 bn CNY |
| Gross profit | 1.42 bn CNY | 1.97 bn CNY |
| Operating income | -1.34 bn CNY | -999.46 m CNY |
| EBIT | -1.31 bn CNY | -1.02 bn CNY |
| Net income | -1.28 bn CNY | -875.17 m CNY |
| Diluted EPS – continuing operations | -1.30 CNY | -0.87 CNY |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
More stocks
- Chipbond Technology (6147.TWO)
- Yuhan Corp. (000100.KS)
- Torex Gold Resources Inc (TXG.TO)
- K92 Mining Inc (KNT.TO)
- FDJ United (FDJ.PA)
- Ramelius Resources Ltd (RMS.AX)
- Cosco Shipping Development Co Ltd (601866.SS)
- Vontier Corp (VNT)
- LS Corp (006260.KS)
- Dottikon ES Holding AG (DESN.SW)
- NOBA Bank Group AB (publ) (NOBA.ST)
- LEG Immobilien (LEG.DE)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.